Michael's research centres on chronic inflammatory disease. He is researching into Loin Pain Haematuria Syndrome (LPHS), considered to be the most painful syndrome known to humanity. He is working on the Crohn's Colitis UK funded EXAT Trial into exercise and the alleviation of Crohn's disease in collaboration with Hertfordshire, Northumbria and Winchester Universities, and Guy's, Bart's, and Hampshire NHS Trusts. He has an interest in novel therapeutics, and is researching into novel heparinoids for the treatment of rheumatoid arthritis, as well as kinases. He has a special interest in the 3Rs and welfare associated with arthritis integrative modelling, working with the Royal Society for the Protection and Care of Animals (RSPCA) as a member of the Rheumatoid Arthritis Models Expert Working Group. He graduated in Pharmacology, with a PhD from the University of Bath, followed by a short term lectureship in Pharmacy and Pharmacology. Having had a placement in experimental surgery and toxicology with Huntingdon Life Sciences, he joined the pharmaceutical industry (Roussel Laboratories and then Hoechst) in arthritis Drug Discovery focussing on in arthritis and angiogenesis disease modelling, drug screening and target validation, and working on leflunomide analogues, phospholipase A2 and matrix metalloproteinase inhibitors. He continued his development of inflammatory, rheumatoid and cancer integrative disease models concentrating on transdermal drug delivery, joint destruction, and angiogenesis in the Department of Experimental Pathology, Saint Bartholomew's Medical College, as an Honorary Senior Lecturer, and then Joint Head of the Experimental Pathology Group at Barts & the London School of Medicine & Dentistry. He held a William Harvey Inflammation Research Fellowship for some years and a Sir Halley Stewart Trust Lectureship lecturing and researching in inflammopharmacology and drug discovery in the Centre for Experimental Medicine and Rheumatology. He worked on dissociated steroid drug discovery developing an integrative modelling programme to separate anti-rheumatic actions from hyperglycaemic and osteoporotic side effects, as well as kinase inhibitors as part of the Macrocept and Kinacept EU CRAFT and FP7 programmes. Michael was an elected Member of Council and Trustee of the British Pharmacological Society (2012-15), and a member of the Education and Outreach Committee. He is now Co-Chair (Basic Science) of the Education Affinity group. He is a Trustee of the League of Mercy, a Liveryman of the Worshipful Society of Apothecaries, and Reader for the Queen's Anniversary Prizes for Higher and Further Education. He is a member of the University Research Ethics Committee, and Legal Sponsor for Clinical Research.